People news: Pfizer, Bausch & Lomb, Sanofi-Aventis, Human Genome Sciences

Pfizer's board of directors elected George Lorch as non-executive chairman of the board. Lorch has been an independent director since 2000 and is chairman emeritus of Armstrong Holdings, a manufacturer of flooring and ceiling materials.

Bausch & Lomb named Daniel Wechsler corporate VP and global president, pharma business. Wechsler joins Bausch & Lomb from Merck, where he was head of US strategy, commercial model innovation and business development.

Sanofi-Aventis named Dr. Elias Zerhouni president, global research and development for medicines and vaccines, and said EVP R&D Marc Cluzel, MD, PhD will resign his post but continue to advise Dr. Zerhouni, who has served as a scientific adviser to CEO Chris Viehbacher since 2009.

Human Genome Sciences named former OSI Pharmaceuticals chief Colin Goddard, PhD to its board of directors.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.